About this Journal Submit a Manuscript Table of Contents
Mediators of Inflammation
Volume 2012 (2012), Article ID 928123, 6 pages
http://dx.doi.org/10.1155/2012/928123
Review Article

Sterile Endophthalmitis after Intravitreal Injections

1Retina and Vitreous Unit, Instituto Oftlamológico Gómez-Ulla, 15705 Santiago de Compostela, Spain
2Department of Ophthalmology, Second University of Naples, 81100 Naples, Italy
3Department of Ophthalmology, University Hospital Complex of Santiago de Compostela, 15706 Santiago de Compostela, Spain

Received 1 July 2012; Accepted 7 August 2012

Academic Editor: Mario R. Romano

Copyright © 2012 Joaquín Marticorena et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. W. Rycroft, “Penicillin and the control of deep intra-ocular infection,” British Journal of Ophthalmology, vol. 29, no. 2, pp. 57–87, 1945.
  2. Endophthalmitis Vitrectomy Study Group, “Results of the endophthalmitis vitrectomy study: a randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis, Endophthalmitis Vitrectomy Study Group,” Archives of Ophthalmology, vol. 113, no. 12, pp. 1479–1496, 1995. View at Scopus
  3. F. K. P. Sutter and M. C. Gillies, “Pseudo-endophthalmitis after intravitreal injection of triamcinolone,” British Journal of Ophthalmology, vol. 87, no. 8, pp. 972–974, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. D. B. Roth, J. Chieh, M. J. Spirn, S. N. Green, D. L. Yarian, and N. A. Chaudhry, “Noninfectious endophthalmitis associated with intravitreal triamcinolone injection,” Archives of Ophthalmology, vol. 121, no. 9, pp. 1279–1282, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. M. L. Nelson, M. T. S. Tennant, A. Sivalingam, C. D. Regillo, J. B. Belmont, and A. Martidis, “Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection,” Retina, vol. 23, no. 5, pp. 686–691, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Özkiriş and K. Erkiliç, “Complications of intravitreal injection of triamcinolone acetonide,” Canadian Journal of Ophthalmology, vol. 40, no. 1, pp. 63–68, 2005. View at Scopus
  7. D. M. Moshfeghi, P. K. Kaiser, S. J. Bakri et al., “Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection,” Ophthalmic Surgery Lasers and Imaging, vol. 36, no. 1, pp. 24–29, 2005. View at Scopus
  8. L. C. Wang and C. M. Yang, “Sterile endophthalmitis following intravitreal injection of triamcinolone acetonide,” Ocular Immunology and Inflammation, vol. 13, no. 4, pp. 295–300, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. J. B. Jonas, I. Kreissig, U. H. Spandau, and B. Harder, “Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide,” American Journal of Ophthalmology, vol. 141, no. 3, pp. 579–580, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Marticorena, F. Gomez-Ulla, M. R. Romano, and I. Luna, “Repeated pseudoendophthalmitis after combined photodynamic therapy and intravitreal triamcinolone,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 245, no. 9, pp. 1403–1404, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. J. L. Carrero, M. G. Barcia, and I. P. Flores, “Sterile endophthalmitis after benzyl alcohol-filtered triamcinolone acetonide injection,” Archives of Ophthalmology, vol. 126, no. 1, pp. 142–143, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Jonisch, J. C. Lai, V. A. Deramo, A. J. Flug, and D. M. Fastenberg, “Increased incidence of sterile endophthalmitis following intravitreal preserved triamcinolone acetonide,” British Journal of Ophthalmology, vol. 92, no. 8, pp. 1051–1054, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. W. Kai, J. Yanrong, and L. Xiaoxin, “Vehicle of triamcinolone acetonide is associated with retinal toxicity and transient increase of lens density,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 244, no. 9, pp. 1152–1159, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. C. K. Yeung, K. P. Chan, S. W. Y. Chiang, C. P. Pang, and D. S. C. Lam, “The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone,” Investigative Ophthalmology and Visual Science, vol. 44, no. 12, pp. 5293–5300, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. C. K. Yeung, K. P. Chan, C. K. M. Chan, C. P. Pang, and D. S. C. Lam, “Cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells: comparison with dexamethasone and hydrocortisone,” Japanese Journal of Ophthalmology, vol. 48, no. 3, pp. 236–242, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. V. L. Morrison, H. J. Koh, L. Cheng, K. Bessho, M. C. Davidson, and W. R. Freeman, “Intravitreal toxicity of the Kenalog vehicle (benzyl alcohol) in rabbits,” Retina, vol. 26, no. 3, pp. 339–344, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Y. Yu, F. M. Damico, F. Viola, D. J. D'Amico, and L. H. Young, “Retinal toxicity of intravitreal triamcinolone acetonide: a morphological study,” Retina, vol. 26, no. 5, pp. 531–536, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. B. W. McCuen, M. Bessler, and Y. Tano, “The lack of toxicity of intravitreally administered triamcinolone acetonide,” American Journal of Ophthalmology, vol. 91, no. 6, pp. 785–788, 1981. View at Scopus
  19. T. Hida, D. Chandler, J. E. Arena, and R. Machemer, “Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations,” American Journal of Ophthalmology, vol. 101, no. 2, pp. 190–195, 1986. View at Scopus
  20. D. Dierks, B. Lei, K. Zhang, and D. P. Hainsworth, “Electroretinographic effects of an intravitreal injection of triamcinolone in rabbit retina,” Archives of Ophthalmology, vol. 123, no. 11, pp. 1563–1569, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Beaudouin, G. Kanny, J. L. Gueant, and D. A. Moneret-Vautrin, “Anaphylaxis to carboxymethylcellulose induced by injectable corticosteroids,” Allergie et Immunologie, vol. 24, no. 9, pp. 333–335, 1992. View at Scopus
  22. E. J. Curry and E. M. Warshaw, “Benzyl alcohol allergy: importance of patch testing with personal products,” Dermatitis, vol. 16, no. 4, pp. 203–208, 2005. View at Scopus
  23. J. Montoro, A. Valero, A. Elices et al., “Anaphylactic shock after intra-articular injection of carboxymethylcellulose,” Allergologia et Immunopathologia, vol. 28, no. 6, pp. 332–333, 2000. View at Scopus
  24. A. A. Moshfeghi, I. U. Scott, H. W. Flynn, and C. A. Puliafito, “Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema,” American Journal of Ophthalmology, vol. 138, no. 3, pp. 489–492, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. R. D. Jager, L. P. Aiello, S. C. Patel, and E. T. Cunningham, “Risks of intravitreous injection: a comprehensive review,” Retina, vol. 24, no. 5, pp. 676–698, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. S. D. M. Chen, J. Lochhead, B. McDonald, and C. K. Patel, “Pseudohypopyon after intravitreal triamcinolone injection for the treatment of pseudophakic cystoid macular oedema,” British Journal of Ophthalmology, vol. 88, no. 6, pp. 843–844, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. J. E. Amato, D. H. Lee, B. A. Santos, and L. Akduman, “Steroid hypopyon following intravitreal triamcinolone acetonide injection in a pseudophakic patient,” Ocular Immunology and Inflammation, vol. 13, no. 2-3, pp. 245–247, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Garay-Aramburu, A. Bilbao-Urtiaga, M. Cuesta-García, and A. Larrauri-Arana, “A case of triamcinolone-induced pseudo-endophthalmitis after vitrectomy,” Archivos de la Sociedad Española de Oftalmología., vol. 80, no. 10, pp. 615–617, 2005. View at Scopus
  29. J. B. Jonas, J. K. Hayler, and S. Panda-Jonas, “Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy,” British Journal of Ophthalmology, vol. 84, no. 9, pp. 1064–1067, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. M. C. Sharma, W. W. Lai, and M. J. Shapiro, “Pseudohypopyon following intravitreal triamcinolone acetonide injection,” Cornea, vol. 23, no. 4, pp. 398–399, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Blanco Marchite, A. Fagúndez, L. Buznego, and J. López-Moya, “Leak of intravitreal triamcinolone to the anterior chamber,” Archivos de la Sociedad Espanola de Oftalmologia, vol. 82, no. 12, pp. 781–783, 2007. View at Scopus
  32. Y. T. Chiu, Y. Y. Tsai, and J. M. Lin, “Noninfectious hypopion after intravitreal triamcinolone acetonide injection for central retinal vein occlusion: a case report,” Kaohsiung Journal of Medical Sciences, vol. 21, no. 10, pp. 466–469, 2005. View at Scopus
  33. J. M. Ruiz-Moreno, J. A. Montero, A. Artola, and S. Barile, “Anterior chamber transit of triamcinolone after intravitreal injection,” Archives of Ophthalmology, vol. 123, no. 1, pp. 129–130, 2005. View at Scopus
  34. J. B. Jonas, J. K. Hayler, A. Söfker, and S. Panda-Jonas, “Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy,” American Journal of Ophthalmology, vol. 131, no. 4, pp. 468–471, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. P. J. Rosenfeld, A. E. Fung, and C. A. Puliafito, “Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion,” Ophthalmic Surgery Lasers and Imaging, vol. 36, no. 4, pp. 336–339, 2005. View at Scopus
  36. P. J. Rosenfeld, A. A. Moshfeghi, and C. A. Puliafito, “Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration,” Ophthalmic Surgery Lasers and Imaging, vol. 36, no. 4, pp. 331–335, 2005. View at Scopus
  37. L. Wu, M. A. Martínez-Castellanos, H. Quiroz-Mercado et al., “Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the pan-american collaborative retina study group (PACORES),” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 246, no. 1, pp. 81–87, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. D. R. Fintak, G. K. Shah, K. J. Blinder et al., “Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab,” Retina, vol. 28, no. 10, pp. 1395–1399, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. O. Artunay, E. Yuzbasioglu, R. Rasier, A. Sengül, and H. Bahcecioglu, “Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection,” Eye, vol. 23, no. 12, pp. 2187–2193, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. D. Y. Chong, R. Anand, P. D. Williams, J. A. Qureshi, and D. G. Callanan, “Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection,” Retina, vol. 30, no. 9, pp. 1432–1440, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. A. E. Fung, P. J. Rosenfeld, and E. Reichel, “The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide,” British Journal of Ophthalmology, vol. 90, no. 11, pp. 1344–1349, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Georgopoulos, K. Polak, F. Prager, C. Prünte, and U. Schmidt-Erfurth, “Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin),” British Journal of Ophthalmology, vol. 93, no. 4, pp. 457–462, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. S. S. Wickremasinghe, K. Michalova, J. Gilhotra et al., “Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration,” Ophthalmology, vol. 115, no. 11, pp. 1911.e1–1915.e1, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. K. Yamashiro, A. Tsujikawa, K. Miyamoto et al., “Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch,” Retina, vol. 30, no. 3, pp. 485–490, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. M. I. van der Reis, E. C. la Heij, Y. de Jong-Hesse, P. J. Ringens, F. Hendrikse, and J. Schouten, “A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections,” Retina, vol. 31, no. 8, pp. 1449–1469, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. S. J. Bakri, T. A. Larson, and A. O. Edwards, “Intraocular inflammation following intravitreal injection of bevacizumab,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 246, no. 5, pp. 779–781, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. C. N. Kay, R. M. Tarantola, K. M. Gehrs, et al., “Uveitis following intravitreal bevacizumab: a non-infectious cluster,” Ophthalmic Surgery, Lasers and Imaging, vol. 42, no. 4, pp. 292–296, 2011.
  48. T. Sato, K. Emi, T. Ikeda et al., “Severe intraocular inflammation after intravitreal injection of bevacizumab,” Ophthalmology, vol. 117, no. 3, pp. 512.e2–516.e2, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. N. M. Yenerel, U. A. Dinc, and E. Gorgun, “A case of sterile endophthalmitis after repeated intravitreal bevacizumab injection,” Journal of Ocular Pharmacology and Therapeutics, vol. 24, no. 3, pp. 362–363, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. D. G. Remick, R. G. Kunkel, J. W. Larrick, and S. L. Kunkel, “Acute in vivo effects of human recombinant tumor necrosis factor,” Laboratory Investigation, vol. 56, no. 6, pp. 583–590, 1987. View at Scopus
  51. Genetech, Avastin (Bevacizumab): Highlights of Prescribing Information, Genetech, San Francisco, Calif, USA, 2011.
  52. E. Hochuli, “Interferon immunogenicity: technical evaluation of interferon-α2a,” Journal of Interferon and Cytokine Research, vol. 17, supplement 1, pp. S15–S21, 1997. View at Scopus
  53. E. Koren, L. A. Zuckerman, and A. R. Mire-Sluis, “Immune responses to therapeutic proteins in humans—clinical significance, assessment and prediction,” Current Pharmaceutical Biotechnology, vol. 3, no. 4, pp. 349–360, 2002. View at Publisher · View at Google Scholar · View at Scopus
  54. The CATT Research Group, “Ranibizumab and bevacizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 364, no. 20, pp. 1897–1908, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Fauser, S. Schroeder, A. Caramoy, B. Kirchhof, and A. Lappas, “Intraocular inflammation after intravitreal ranibizumab injections,” Acta Ophthalmologica, vol. 89, no. 1, pp. e98–e99, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. S. Sharma, D. Johnson, M. Abouammoh, et al., “Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections,” Canadian Journal of Ophthalmology, vol. 47, no. 3, pp. 275–279, 2012.
  57. J. R. Smith, J. T. Rosenbaum, D. J. Wilson et al., “Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement,” Ophthalmology, vol. 109, no. 9, pp. 1709–1716, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. S. Frenkel, K. Hendler, T. Siegal, et al., “Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience,” British Journal of Ophthalmology, vol. 92, no. 3, pp. 383–388, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. S. P. Holland, D. W. Morck, and T. L. Lee, “Update on toxic anterior segment syndrome,” Current Opinion in Ophthalmology, vol. 18, no. 1, pp. 4–8, 2007. View at Publisher · View at Google Scholar · View at Scopus